<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366024</url>
  </required_header>
  <id_info>
    <org_study_id>XQonc-016</org_study_id>
    <nct_id>NCT04366024</nct_id>
  </id_info>
  <brief_title>A Novel Nomogram to Predict Severity of COVID-19</brief_title>
  <official_title>A Novel Nomogram to Predict Severity of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators use clinical data from a large sample of COVID-19 disease patients to screen
      out biomarkers associated with disease severity. Then, a novel nomogram model will be
      established to predict covid-19 disease severity, which could provide important assistance
      and supplement for clinical work. In the case of extremely shortage of front-line medical
      resources, patients with potential severe diseases will be timely treated with the help of
      the novel nomogram model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the consistency of predicted severe rate and observed severe rate of COVID-19 patients</measure>
    <time_frame>up to 3 months</time_frame>
    <description>We aim to use the clinical data of COVID-19 patients to construct a nomogram model to predict the severe rate of each patient, then the the consistency of predicted severe rate and observed severe rate will be evaluated by calibration plot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of severe illness</measure>
    <time_frame>up to 3 months</time_frame>
    <description>the duration of severe illness of each patient will evaluated</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19 Disease</condition>
  <condition>Nomogram Model</condition>
  <arm_group>
    <arm_group_label>Observed group</arm_group_label>
    <description>COVID-19 disease patients who were detected by RT-PCR and CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>other</intervention_name>
    <description>clinical diagnosis</description>
    <arm_group_label>Observed group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 disease patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 disease patients confirmed by virus nucleic acid RT-PCR and CT

        Exclusion Criteria:

          -  unconfirmed suspected cases

          -  Patients during pregnancy and lactation

          -  incomplete clinical data

          -  investigators considered patients ineligible for the trial

          -  Child patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jianguo Sun</last_name>
    <phone>023-68774490</phone>
    <email>sunjg09@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinqiao Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Jianguo</last_name>
      <email>yanmaizhixiang@sina.cn</email>
    </contact>
    <contact_backup>
      <phone>023774490</phone>
      <phone_ext>0086</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Jianguo Sun</investigator_full_name>
    <investigator_title>Deputy Director,Head of Oncology department, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

